Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2

Gynecologic Oncology

Volumn 137, Issue 1, 2015, Pages 86-92

  Minion, Lindsey E ^a   Dolinsky, Jill S ^b   Chase, Dana M ^c   Dunlop, Charles L ^b   Chao, Elizabeth C ^b,d   Monk, Bradley J ^c  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b AMBRY GENETICS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA1; BRCA2; Hereditary; Lynch syndrome; Multi gene; Next generation sequencing

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; MRE11 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN BRIP1; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MRE11A; PROTEIN MSH2; PROTEIN NBN; PROTEIN P53; PROTEIN PALB2; RAD50 PROTEIN; RAD51 PROTEIN; RAD51C PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ATM PROTEIN, HUMAN; BRIP1 PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; RNA HELICASE;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL STUDY; DIAGNOSTIC VALUE; FAMILIAL CANCER; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; POPULATION; PRIORITY JOURNAL; BREAST TUMOR; COHORT ANALYSIS; GENETIC SCREENING; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CHECKPOINT KINASE 2; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RNA HELICASES; YOUNG ADULT;

EID: 84929942719     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.01.537     Document Type: Article

References (40)

1. Siegel R, Naishadham N, Jemal A. Cancer statistics, 2013. CA Cancer J Clin Jan 2013; 63(1):11-30.
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol Apr 2013;10(4): 211-24.
3. Kauff ND, Satagopan JM, Robson ME, Scheuler L, Hensley M, Clifford AH, et al. Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med May 23 2002;346(21):1609-15.
4. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reduction salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst Jan 21 2009;101(2):80-7.
5. Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med Sep 6 2005;143(5):362-79.
6. American Cancer Society. Facts and Figs. http://www.cancer.org/acs/groups/ content/@research/documents/webcontent/acspc-042151.pdf; 2014.
7. Weisman SW, Weiss SM, Newlin AC. Genetic testing by cancer site ovary. Cancer J Jul-Aug 2012;18(4):320-7.
8. Van der Groep P, Van derWall E, Van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol Apr 2011;34(2):71-88.
9. Miki Y, Swensen J, Shattuck-Eidens D, Futreal A, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science Oct 7 1994;266(5182):66-71.
10. Wooster R, Bignell G, Lancaster J, Collins N, Gregory S, Gumbs C, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature Dec 21-28 1995;378(6559): 789-92.
11. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/familial High-Risk Assessment: Breast and Ovarian (version 4.2013). http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. (Accessed February 22, 2014).
12. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risk of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet May 2003;72(5):1117-30.
13. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer Jun 2013;12(2):273-7.
14. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet Jan 1997;6(1):105-10.
15. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A Nov 1 2011;108(44): 18032-7.
16. Meindl A, Hellbrand K, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet May 2010;42(5):410-4.
17. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS. Clinical evaluation of multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol Jul 1 2014;32(19):2001-9.
18. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet Oct 2 2011;43(11): 1104-7.
19. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA Mar 22 2006;295(12):1379-88.
20. Coulet F, Fajac A, Colas C, Eyries M, Dion-Miniere A, Rouzier R, et al. Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet Apr 2013;83(4): 332-6.
21. Damiola F, Pertesi M, Oliver J, Calvez-Kelm FL, Voegele C, Young EL, et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case- control mutation-screening study. Breast Cancer Res Jun 3 2014;16(3):R58.
22. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med May 20 2010;362(20):1909-19.
23. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breastcancer risk in families with mutations in PALB2. N Engl J Med Aug 7 2014;371(6): 497-506.
24. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PLAB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutations-negative breast and/or ovarian cancer individuals. Breast Cancer Res Feb 28 2011;13(1):R20.
25. Thorstenson YR, Roxas A, Kroiss R, JenkinsMA, Yu KM, Bachrich T, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res Jun 15 2003; 63(12):3325-33.
26. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res Feb 1 2014;20(3):764-75.
27. Casadei S, Norquist BM, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res Mar 15 2011;71(6):2222-9.
28. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet Aug 15 2011; 20(16):3278-88.
29. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol Feb 2012;124(2):347-53.
30. Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol Oct 2004; 95(1):62-9.
31. Castera L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Nextgeneration sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet Nov 2014;22(11):1305-13.
32. Kanchi KL, Johnson KJ, Lu C, McLellanMD, LeisersonMDM, WendlMC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014;5:3156.
33. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer Jan 2003;3(1):23-34.
34. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med Apr 2008;10(4):294-300.
35. LaDuca H, Stuenkel AJ, Dolinshky JS, Keiles SK, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. Genet Med Apr 2014;24.
36. Tan DSP, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanely S, et al. "BRCA" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol Dec 1 2008;26(34):5530-6.
37. Pennington KP, Walsh T, HarrellM, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube and peritoneal carcinomas. Clin Cancer Res Feb 1 2014;20(3):764-75.
38. Chong HK, Wang T, Lu HM, Seider S, Lu H, Keiles S, Chao EC, et al. The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer assay. PLoS One May 15 2014;9(5):e97408.
39. Konstantinopoulos PA, Spentzos D, Karlan B, Taniguchi T, Founzilas E, Fancoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol Aug 1 2010;28(22):3555-61.
40. Wysham WZ, Mhawech-Faucegila P, Li H, Hays L, Syriac S, Skrepnik T, et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012;7(1):e30042.